Silicon-Containing Cationic Lipids for Lower-Cost Nanoparticle Preparation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The preparation of cationic lipid nanoparticles for active agent delivery is hindered by high costs and inefficiencies in current processes, and there is a need for biodegradable cationic lipids that facilitate better degradation post-delivery.
Innovation Solution
Development of cationic lipids with specific hydrocarbyl and nitrogen-containing groups, allowing for efficient and less expensive production, and incorporation into lipid nanoparticles that are biodegradable.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current cationic lipid preparation processes are used, then nanoparticles can be formed for active agent delivery, but the preparation cost is high and the process is inefficient
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by incorporating silicon atoms at specific positions (α, β, or γ positions relative to the nitrogen atom) and using specific hydrocarbyl groups (C2-C30) with controlled saturation levels. These parameter changes in molecular structure enable the lipids to form effective nanoparticles while being synthesizable through more cost-efficient and scalable processes compared to traditional cationic lipids.
2Reliability
If conventional cationic lipids are used for nanoparticle delivery, then active agents can be delivered effectively, but the nanoparticles do not degrade well post-delivery
Solution Approach 1:
The patent introduces biodegradable features at specific local positions within the cationic lipid molecule. The silicon atom is placed at the α, β, or γ position relative to the nitrogen atom, and hydrocarbyl groups with specific chain lengths and saturation levels are used. These localized modifications enable controlled degradation at target sites while preserving the overall nanoparticle structure and delivery effectiveness during circulation.
Data Source
AI summary
Certain embodiments of the invention provide a cationic lipid of formula (I):wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.